|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Collaboration revenue | |||||
| Operating expenses: | |||||
| Research and development | |||||
| General and administrative | |||||
| Total operating expenses | |||||
| Loss from operations | |||||
| Other income: | |||||
| Interest income | |||||
| Foreign currency exchange gain, net | |||||
| Gain on disposal of fixed assets | |||||
| Loss on sale of marketable securities | |||||
| Total other income | |||||
| Net loss before income taxes | |||||
| Income tax benefit (provision) | |||||
| Net loss | |||||
| Other comprehensive loss: | |||||
| Provision for pension benefit obligation | |||||
| Unrealized gain on available-for-sale securities | |||||
| Comprehensive loss | |||||
| Net loss per share attributable to common stockholders - basic | |||||
| Net loss per share attributable to common stockholders - diluted | |||||
| Weighted-average number of common shares used in computing net loss per share - basic | |||||
| Weighted-average number of common shares used in computing net loss per share - diluted | |||||
Loading...